ACADIA Pharmaceuticals (ACAD) News Today $16.27 +0.06 (+0.37%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without CauseNovember 21 at 7:20 AM | marketwatch.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 972,665 shares of the biopharmaceuticaNovember 21 at 5:44 AM | marketbeat.comFY2027 Earnings Estimate for ACAD Issued By Leerink PartnrsNovember 21 at 2:10 AM | americanbankingnews.comFY2027 Earnings Forecast for ACAD Issued By Leerink PartnrsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a report released on Sunday, November 17th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceuticalNovember 20 at 7:18 AM | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $68,467.13 in StockNovember 20 at 6:02 AM | insidertrades.comResearch Analysts Set Expectations for ACAD FY2024 EarningsNovember 20 at 1:17 AM | americanbankingnews.comACADIA Pharmaceuticals: Untapped Potential with Financial Stability and Strategic Growth OpportunitiesNovember 19 at 12:37 PM | markets.businessinsider.comFY2024 Earnings Estimate for ACAD Issued By Leerink PartnrsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued on Sunday, November 17th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmacNovember 19 at 6:36 AM | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Lowered to Buy Rating by StockNews.comNovember 17, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Up 16.5% in OctoberNovember 17, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short InterestACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 9,530,000 shares, a growth of 16.5% from the October 15th total of 8,180,000 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is currently 7.0 days.November 16, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Holdings Lessened by GSA Capital Partners LLPGSA Capital Partners LLP cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 62.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,096 shares of the biophNovember 16, 2024 | marketbeat.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 15, 2024 | businesswire.comCentessa Pharmaceuticals (CNTA) Receives a Buy from Morgan StanleyNovember 14, 2024 | markets.businessinsider.comEquities Analysts Offer Predictions for ACAD FY2024 EarningsNovember 13, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have earned an average rating of "Moderate Buy" from the seventeen analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eleven have giveNovember 13, 2024 | marketbeat.comUS Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)US Bancorp DE boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 2,084.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,934 shares of the biopharmaceuticalNovember 12, 2024 | marketbeat.comAcadia Pharmaceuticals: Proving The Naysayers WrongNovember 11, 2024 | seekingalpha.comWhat is Leerink Partnrs' Forecast for ACAD FY2026 Earnings?ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at Leerink Partnrs lifted their FY2026 earnings estimates for ACADIA Pharmaceuticals in a report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will poNovember 11, 2024 | marketbeat.comEquities Analysts Issue Forecasts for ACAD FY2024 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst A. Fein now anticipNovember 11, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Receives "Buy" Rating from HC WainwrightNovember 11, 2024 | americanbankingnews.comAcadia Pharmaceuticals price target lowered to $32 from $33 at CanaccordNovember 10, 2024 | markets.businessinsider.comBuy Recommendation for Acadia Pharmaceuticals Driven by Strong Nuplazid Performance and Promising PipelineNovember 10, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting NextNovember 10, 2024 | finance.yahoo.comStrong Market Performance and Growth Prospects Justify Buy Rating for ACADIA PharmaceuticalsNovember 8, 2024 | markets.businessinsider.comHC Wainwright Analysts Decrease Earnings Estimates for ACADACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at HC Wainwright cut their Q4 2024 EPS estimates for shares of ACADIA Pharmaceuticals in a report released on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical companyNovember 8, 2024 | marketbeat.comACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats ExpectationsNovember 8, 2024 | finance.yahoo.comACADIA Pharmaceuticals: Strong Q3 Performance and Strategic Growth Initiatives Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...November 7, 2024 | finance.yahoo.comCautious Outlook for ACADIA Pharmaceuticals Amid Strategic Initiatives and Growth ChallengesNovember 7, 2024 | markets.businessinsider.comACADIA Pharmaceuticals: Strong Sales and Strategic Vision Underpin Buy RatingNovember 7, 2024 | markets.businessinsider.comACADIA Pharmaceuticals (NASDAQ:ACAD) Announces Earnings ResultsACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.07. ACADIA Pharmaceuticals had a net margin of 3.43% and a return on equity of 6.89%. The company had revenue of $250.40 million for the quarter, compared to analysts' expectations of $248.83 million. During the same quarter last year, the company earned ($0.40) earnings per share. The firm's revenue for the quarter was up 18.3% on a year-over-year basis.November 7, 2024 | marketbeat.comACADIA Pharmaceuticals' (ACAD) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday.November 7, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday.November 7, 2024 | marketbeat.comACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call TranscriptNovember 6, 2024 | seekingalpha.comACADIA Pharmaceuticals Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 6, 2024 | seekingalpha.comAcadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating OverviewNovember 6, 2024 | businesswire.comNeuren Pharmaceuticals Gains from Voucher SaleNovember 6, 2024 | markets.businessinsider.comAcadia Pharma Q3 2024 Earnings PreviewNovember 6, 2024 | msn.comAcadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review VoucherNovember 6, 2024 | marketwatch.comAcadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 MillionNovember 5, 2024 | businesswire.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by AlphaCentric Advisors LLCAlphaCentric Advisors LLC reduced its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 60.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,000 shares of the biopharmaceuNovember 5, 2024 | marketbeat.comACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024November 1, 2024 | msn.comACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024November 1, 2024 | msn.comACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on WednesdayACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=333822)October 30, 2024 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 12-Month Low - Here's What HappenedACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week Low - What's Next?October 23, 2024 | marketbeat.comDo Options Traders Know Something About Acadia (ACAD) Stock We Don't?October 22, 2024 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Rating of "Moderate Buy" from AnalystsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has received a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and eleven have assignedOctober 19, 2024 | marketbeat.comHealth Canada approves Acadia’s DAYBUE for Rett syndromeOctober 18, 2024 | msn.comAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024October 17, 2024 | businesswire.com Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide ACAD Media Mentions By Week ACAD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.040.46▲Average Medical News Sentiment ACAD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼187▲ACAD Articles Average Week Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arrowhead Pharmaceuticals News Ionis Pharmaceuticals News Jazz Pharmaceuticals News Catalent News Sarepta Therapeutics News Revolution Medicines News Qiagen News Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts